There exists limited information about the usefulness of hemopoietic stem cell transplantation (HSCT) for the treatment of patients with refractory Langerhans cell histiocytosis (LCH). We report here four Japanese pediatric patients with multisystem LCH disease who underwent HSCT between 1994 and 1997. Two of the four patients are doing well without any relapse. However, neither of them shows improved sequelae 3 to 4 years after allogeneic HSCT, although the graft was rejected in one of the cases. The remaining two patients died of septic shock. A review of the literature of 11 patients revealed four fatalities after the use of HSCT in the treatment of LCH. Three of these were due to active LCH and three deaths occurred within 2 months after HSCT. To establish the usefulness of HSCT for refractory LCH, further studies are required.
Summary:
There exists limited information about the usefulness of hemopoietic stem cell transplantation (HSCT) for the treatment of patients with refractory Langerhans cell histiocytosis (LCH). We report here four Japanese pediatric patients with multisystem LCH disease who underwent HSCT between 1994 and 1997. Two of the four patients are doing well without any relapse. However, neither of them shows improved sequelae 3 to 4 years after allogeneic HSCT, although the graft was rejected in one of the cases. The remaining two patients died of septic shock. A review of the literature of 11 patients revealed four fatalities after the use of HSCT in the treatment of LCH. Three of these were due to active LCH and three deaths occurred within 2 months after HSCT. To establish the usefulness of HSCT for refractory LCH, further studies are required. Keywords: hematopoietic stem cell transplantation; Langerhans cell histiocytosis There is no established treatment for Langerhans cell histiocytosis (LCH) because the pathogenesis of this disease is still not clear. For patients with multisystem LCH, various types of combination chemotherapy are available with a 4-year relapse-free survival rate of 50-70%. [1] [2] [3] [4] However, in severe cases of LCH, the disease reaches such an advanced stage that patients eventually succumb despite heavy chemotherapy. In such patients, HSCT has been attempted as a salvage therapy in the hope of developing an effective therapeutic strategy for this disease. We report here four cases in Japan.
Case reports
Three of the four cases were recruited when we conducted the second national survey for newly diagnosed patients with LCH between 1991 and 1995. 5 One patient was registered with the current protocol of the LCH study group of Japan. 6 The patients' profiles before HSCT are summarized in Table 1 .
Patient 1
A 1 year and 9 months old boy, had LCH lesions in the skin, bone, lymph node, liver, spleen and lungs, which diagnosis was confirmed by positive Birbeck granules. The patient received multiagent chemotherapy but progressed to have diabetes insipidus, ear tumor and pancytopenia. Despite heavy chemotherapy including etoposide (VP-16, total dose 3500 mg), vincristine (VCR), methotrexate (MTX), irradiation (Rad) and interferon-␥ (IFN-␥), he had three recurrences. Two and a half years after the diagnosis, CD34-positive cell-selected BMT was performed from a two loci mismatched sibling.
Patient 2
An 11-month-old boy, had LCH lesions in the skin, bone, lymph node, liver, spleen and lungs. Unresponsive to treatment with VP-16, cyclophosphamide (CY) and adriamycin (ADR), the disease progressed with bone marrow infiltration. Three years and 11 months after the diagnosis, allogeneic BMT from an HLA-matched sibling was performed. Because of progressive pancytopenia after engraftment of bone marrow cells, 3 months after the first BMT, the patient received additional allogeneic peripheral blood stem cell transplantation (PBSCT) from the same donor.
Patient 3
A 12 years and 10 months old girl, had multiple bone and skin involvements of LCH. Following 10 months of treatment with prednisolone (Pred), vinblastine (VBL), MTX and cyclosporine (CyA), the patient showed progressive pancytopenia and recurrent fever. Bone marrow was hypoplastic showing no apparent involvement of LCH. The patient received syngeneic BMT from an identical twin sibling. 
Patient 4
A 7-month-old boy, had multiple LCH lesions in the skin, bone, lymph node, liver, spleen, lungs and bone marrow. He was treated with multiagent chemotherapy including VP-16 (total dose 750 mg), Pred, VCR, MTX, CyA and ADR. Despite continuous chemotherapy for 3 months, the disease recurred with fever and joint pain. Thereafter, he received the treatment regimen of the LCH study group of Japan, consisting of ACOP (ADR, VCR, CY, Pred). After three courses of treatment, he was maintained on a biweekly combination of AOP (ADR, VCR, Pred), MTX/Pred and COP (CY/VCR/Pred) therapy for 3 months, which resulted in pancytopenia. Nine months after the initial diagnosis, he received allogeneic BMT from his HLA matched brother.
Post-transplant therapeutic results (Table 2)
In case 1, the donor CD34 + cells were rejected but the patient, nonetheless, experienced autorecovery 30 days Table 2 Details of hematopoietic stem cell transplantation and outcome after HSCT. Fortunately, he has experienced no relapse since and has been well for the 34 months post-transplantation period, which corresponds to 5 years since diagnosis. As for sequelae, he has unimproved conductive deafness and diabetes insipidus, which has been well controlled by DDAVP therapy. In case 2, the first BMT engrafted on day 18 after the transplant. He died of septic shock 9 days following the PBSCT, which was performed for the rescue of severe pancytopenia. In case 3, donor bone marrow was successfully engrafted 15 days after BMT and since then the patient has done well without any relapse. However, there has been no visible improvement of long-lasting tinnitus since diagnosis. In case 4, septic shock occurred 9 days after transplantation and was fatal. The exact stage of the disease at death in the two fatal cases was not clear because no autopsy was permitted.
Review of the HSCT cases in the literature
As shown in Table 3 , 11 HSCT cases for refractory LCH were collected from the literature. [7] [8] [9] [10] [11] [12] [13] The age at HSCT 937 Table 3 Reported HSCT cases for refractory LCH ranged from 0.25 to 45 years, and nine out of 11 cases received allogeneic grafts. Also TBI was employed in nine of the 11 HSCT cases as a conditioning regimen. Four deaths were recorded, of which three were due to relapsed/progressed LCH; however, in one case, no active LCH was noted at death. At the time of documentation, seven cases were still alive with remission times ranging from 12 to 168 months.
Discussion
Of the four HSCT recipients with refractory LCH, we considered that HSCT was an inevitable option because they all had multisystem LCH which was refractory to multiagent chemotherapy. It should be noted that two of the cases died of septic shock during the post-HSCT period, probably as a result of pancytopenia which was either transplant-related or associated with the original disease. In the literature survey, one fatal case of systemic adenovirus infection was also found. 13 Two of our four cases are alive and well without any subsequent relapse being observed in the 34 month period (case 1) and 49 month period (case 3) following HSCT. Although the LCH disease of these patients seems to be currently in an inactive state, their sequelae have persisted. In case 1, DI persisted after transplantation. He continues to suffer from conductive deafness the cause of which remains obscure. The tinnitus in case 3 did not disappear after transplantation. It is apparent that such complications cannot be cured by HSCT, unless HSCT is performed at an early and appropriate time in disease development.
What are the risk factors in the use of HSCT for refractory LCH? Because of the limited number of trials, these risks still remain unknown. The patients' age, disease activity, type of HSCT, conditioning regimens, methods of GVHD prophylaxis and HSCT-related complications may all be important and should be taken into consideration. Of the 11 cases described in the literature, seven cases received allogeneic BMT from HLA-matched donors, two autologous BMT, and two allogeneic PBSCT. Seven patients are still alive. Four patients died because of either LCH relapse (three cases) or pulmonary infection (one case). Even if we combine the HSCT cases reported here with the other previously reported cases, their number is still too small to draw any firm conclusions. Although it is difficult to evaluate the impact of the conditioning regimen in case 1 where donor CD34 + cells were rejected prior to autorecovery, the conditioning regimen may have contributed to the eradication of the pathological LCH cells in this refractory patient.
In our limited experience, persistent pancytopenia is held to be an ominous sign. Pancytopenia in LCH patients may be caused by bone marrow invasion or transplant (therapy)-related myelosuppression. Technically, we can detect positive cells in the bone marrow stained with CD1a monoclonal antibody, 14 which is useful in the evaluation of bone marrow invasion. However, in the present cases, we were unable to explain the observed pancytopenia because the CD1a staining data were not available.
In allogeneic HSCT for patients with malignant disorders, the antitumor activity like the graft-versus-leukemia effect is exerted by donor cells. In this study, no superiority of allogeneic HSCT was confirmed in cases of LCH, although in many LCH cases clonality has been confirmed. 15 One of the reasons is that HSCT can only be justified when the cases are progressive, refractory to chemotherapy when patients probably have insufficient immunological function. Although we believe that HSCT has the potential to cure LCH, its ultimate usefulness against refractory LCH remains to be determined using a larger number of cases. Further advances in our knowledge of the pathogenetic mechanism of the underlying disorder will be required if we wish to define better therapies including HSCT for LCH patients in the future.
